The estimated Net Worth of Christopher Cabell is at least 937 千$ dollars as of 25 November 2020. Dr Cabell owns over 2,500 units of Arena Pharmaceuticals Inc stock worth over 249,975$ and over the last 4 years he sold ARNA stock worth over 0$. In addition, he makes 687,102$ as Advisor at Arena Pharmaceuticals Inc.
Sign up
Dr MHS ARNA stock SEC Form 4 insiders trading
Dr has made over 2 trades of the Arena Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,500 units of ARNA stock worth 249,975$ on 25 November 2020.
The largest trade he's ever made was exercising 13,000 units of Arena Pharmaceuticals Inc stock on 2 June 2020 worth over 341,640$. On average, Dr trades about 2,214 units every 25 days since 2020. As of 25 November 2020 he still owns at least 2,500 units of Arena Pharmaceuticals Inc stock.
You can see the complete history of Dr Cabell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Christopher H. Cabell FACC, M.D., MHS biography
Dr. Christopher H. Cabell FACC, M.D., MHS is the Advisor at Arena Pharmaceuticals Inc.
What is the salary of Dr MHS?
As the Advisor of Arena Pharmaceuticals Inc, the total compensation of Dr MHS at Arena Pharmaceuticals Inc is 687,102$. There are 5 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of 8,931,400$.
What's Dr MHS's mailing address?
Christopher's mailing address filed with the SEC is C/O PULMATRIX, INC., 99 HAYDEN AVE, , LEXINGTON, MA, 02421.
Insiders trading at Arena Pharmaceuticals Inc
Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over 9,243,184$ worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth 252,505$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Manmeet Singh Soni、Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of 3,133,387$. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth 48,190$.
What does Arena Pharmaceuticals Inc do?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
What does Arena Pharmaceuticals Inc's logo look like?
Complete history of Dr Cabell stock trades at Arena Pharmaceuticals Inc、Pulmatrix Inc
Arena Pharmaceuticals Inc executives and stock owners
Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Amit Munshi,
Director, President and Chief Executive Officer -
Vincent Aurentz,
Executive Vice President and Chief Business Officer -
Robert Lisicki,
Executive Vice President and Chief Commercial Officer -
Amit D. Munshi M.B.A.,
Pres, CEO & Director -
Vincent E. Aurentz,
Exec. VP & Chief Bus. Officer -
Dr. Christopher H. Cabell FACC, M.D., MHS,
Advisor -
Laurie D. Stelzer,
Exec. VP & CFO -
Joan Schmidt,
Exec. VP, Gen. Counsel & Sec. -
Tina Nova,
Independent Chairman of the Board -
Jennifer Jarrett,
Independent Director -
Randall Woods,
Independent Director -
Jayson Dallas,
Independent Director -
Manmeet Soni,
Independent Director -
Kieran Gallahue,
Independent Director -
Oliver Fetzer,
Independent Director -
Garry Neil,
Independent Director -
Katharine Knobil,
Director -
Joan Schmidt,
Executive Vice President, General Counsel, Secretary -
Laurie Stelzer,
Chief Financial Officer, Executive Vice President -
Patrick Malloy,
VP of Investor Relations & Corp. Communications -
Megan E. Knight,
Director of Investor Relations -
Dr. Lamine Mbow Ph.D.,
Sr. VP & Chief Scientific Officer -
Dr. Douglas A. Bakan Ph.D.,
Exec. VP of Technical Operations -
Harry F Jr Hixson,
Director -
Maurice James Mezzino,
SVP, Corporate Development -
Phillip M Schneider,
Director -
Preston Klassen,
EVP and CMO -
Steven W Spector,
EVP, General Counsel & Sec -
Scott H Bice,
Director -
Kevin Robert Lind,
Executive VP and CFO -
Christine Anna White,
Director -
Donald D Belcher,
Director -
Nawal Ouzren,
Director -
Frederick Frank,
-
Mark N Lampert,
Director -
Robert Hoffman,
SVP, Finance and CFO -
Partners L P/Ilbiotechnolog...,
-
James Laforce,
Director -
Jennifer Kathleen Bielasz,
VP, Accounting & Controller -
K A Ajit Simh,
VP, Quality Systems -
Jack Lief,
Chairman, President and CEO -
Craig Michael Audet,
SVP, Opn & Head Glob Reg Afrs -
Duke K Bristow,
Director -
Robert L Toms,
Director -
Paul W Maffuid,
VP, Pharmaceutical Development -
Joyce H Williams,
VP, Drug Development -
Partners L P/Ilbvf Inc/Ilbi...,
-
Nigel R A Beeley,
VP, Chief Chemical Officer -
Joseph F Mooney,
Chief Financial Officer -
Derek T Chalmers,
Vice President, Research -
Louis J Scotti,
VP, Marketing and Bus Dev -
Dominic P Behan,
EVP & Chief Scientific Officer -
James Edeerfield Capital Lp...,
-
Louis J Jr Lavigne,
Director -
William R Jr Shanahan,
SVP & Chief Medical Officer -
Christopher Cabell,
EVP, Head of R&D, and CMO -
Steven J Schoch,
Director -
Douglas J. Manion,
EVP Research & Development